Mutations of the human hepatic lipase gene in patients with combined hypertriglyceridemia/hyperalphalipoproteinemia and in patients with familial combined hyperlipidemia

Citation
S. Gehrisch et al., Mutations of the human hepatic lipase gene in patients with combined hypertriglyceridemia/hyperalphalipoproteinemia and in patients with familial combined hyperlipidemia, J MOL MED-J, 77(10), 1999, pp. 728-734
Citations number
25
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research General Topics
Journal title
JOURNAL OF MOLECULAR MEDICINE-JMM
ISSN journal
09462716 → ACNP
Volume
77
Issue
10
Year of publication
1999
Pages
728 - 734
Database
ISI
SICI code
0946-2716(199910)77:10<728:MOTHHL>2.0.ZU;2-9
Abstract
Hepatic lipase is an enzyme which hydrolyzes triglycerides from plasma lipo proteins and thus takes part in the metabolism of intermediate density lipo proteins and high-density lipoproteins. The search described here concentra ted on mutations of the HL gene in 129 patients with combined hypertriglyce ridemia/hyperalphalipoproteinemia and in 184 members of 19 families with fa milial combined hyperlipidemia. Controls were 100 subjects with favorable l ipid values (age 46-51 years). Mutation screening and analysis were perform ed by temperature-gradient gel electrophoresis, allele-specific restriction ,genotyping, and sequencing. Six different missense mutations and four diff erent silent mutations were found in the HL gene. The alleles Phe-267 and G ln-343 were detected only once in the patient group with hypertriglyceridem ia and hyperalphalipoproteinemia and were not detected in the control group . The allele Met-383 was rare in both patients and controls. We found 9.3% of the patients and only 3.0% of controls to be carrying the Val-73-Met mis sense mutation. The allele Phe-334 was found in 5.43% of patients and in 2. 0% of controls. The difference between the frequencies of these alleles was significant between male patients and male controls (Met-73 P=0.044; Phe-3 34 P=0.047). Also, the summarized odds ratio of 3.28 (95% confidence interv al 1.23-8.73) demonstrates that mutation carriers are significantly more pr evalent in the patients. Fifteen carriers of the Met-73 allele were found i n six families of the familial combined hyperlipidemia group. Furthermore, six carriers of the Phe-334 allele were found in three families of the same group. In comparison to the controls the summarized odds ratio of 2.45 (95 % confidence interval 0.89-6.71) barely missed the level of significance. T he linkage between genotype and phenotype was incomplete. These results sho w an association of the missense mutations Val-73-Met and Leu-334-Phe as su sceptibility alleles for combined forms of hyperlipidemia.